RxDoctor Payments Data

Christopher Galuardi, MD

Interventional Pain Medicine · Berlin, MDNPI 1396755286

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,597 of the $3,506 with a category attached, or 74.1%. 14 manufacturers reported payments, led by Pacira Pharmaceuticals Incorporated at 27.2% of the total. Reporting peaked in 2024 at $1,587 and has fallen 85.3% since, to $233 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in MD, where the typical reported total is $3,506.

$3,506in general payments, 2019–2025

Across 64 payments — averaging $54.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$952
  • Abbott$671
  • Medtronic$591
  • Nevro Corp.$286
  • AbbVie$252
  • Pacira Therapeutics, Inc.$203
  • plus $551 from 8 others

What the payments were for

  • Travel & lodging$91026%
  • Food & beverage$2,59774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,506 in reported general payments places this provider in the 50th percentile of 56 interventional pain medicine providers in Maryland.

See all interventional pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$493,108
Medicare patients
603
Services billed
8,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl15$26,426
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen458$12,014
Oxycodone Hcl404$7,242
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen218$6,277
Gabapentin368$6,019
Lidocaine73$5,800
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$5,311
Duloxetine Hcl205$5,206
Tramadol Hcl ErTramadol Hcl62$4,946
Pregabalin110$4,289
Metaxalone18$3,790
Fentanyl38$3,630
Celecoxib61$3,341
Baclofen164$2,967
Morphine Sulfate ErMorphine Sulfate40$2,840

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Berlin

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →